Drug profile · INN
islelizumab-jsgr
TEVIMBRA
islelizumab-jsgr (TEVIMBRA) is a programmed cell death protein 1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — islelizumab-jsgr
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
islelizumab-jsgr (TEVIMBRA) is a programmed cell death protein 1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Programmed cell death protein 1 inhibitor
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is islelizumab-jsgr?
islelizumab-jsgr (TEVIMBRA) is a programmed cell death protein 1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for islelizumab-jsgr?
TEVIMBRA is a marketed brand name for islelizumab-jsgr. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of islelizumab-jsgr?
islelizumab-jsgr has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.